Certara (NASDAQ:CERT) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Certara (NASDAQ:CERT) released its quarterly earnings data on Thursday. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03, FiscalAI reports. The business had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.17%. During the same period in the prior year, the company earned $0.13 EPS. Certara updated its FY 2025 guidance to 0.450-0.470 EPS.

Certara Trading Down 23.1%

CERT stock traded down $2.60 during mid-day trading on Friday, reaching $8.67. The company’s stock had a trading volume of 9,104,388 shares, compared to its average volume of 1,604,633. Certara has a 12 month low of $8.47 and a 12 month high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average price is $11.77 and its 200 day moving average price is $11.51. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 123.86 and a beta of 1.44.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CERT. Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Certara in a research report on Wednesday, October 8th. UBS Group cut their price target on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. KeyCorp upped their price objective on Certara from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Finally, Craig Hallum began coverage on shares of Certara in a report on Monday, September 29th. They issued a “buy” rating and a $16.00 price objective for the company. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $15.38.

Insider Activity

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.33% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Certara in the first quarter worth approximately $259,000. Goldman Sachs Group Inc. increased its holdings in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after acquiring an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC lifted its holdings in shares of Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Certara by 29.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after purchasing an additional 21,099 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.